Exam quality of ultrasound and dynamic contrast-enhanced abbreviated MRI and impact on early-stage HCC detection
Authors:
- Karim Seif El DahanKDKarim Seif El Dahan
- Takeshi YokooTYTakeshi Yokoo
- Mishal Mendiratta-LalaMMMishal Mendiratta-Lala
- David FetzerDFDavid Fetzer
- Matthew DavenportMDMatthew Davenport
- Darine DaherDDDarine Daher
- Nicole E. RichNRNicole E. Rich
- Edward YangEYEdward Yang
- Neehar D. ParikhNPNeehar D. Parikh
- Amit G. SingalASAmit G. Singal
- 15 November 2024
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (5) , 2097-2109
Abstract
Purpose MRI is a potential alternative to ultrasound for hepatocellular carcinoma (HCC) detection. We evaluated the impact of ultrasound and dynamic abbreviated MRI (AMRI) exam quality on early-stage HCC detection. Methods We conducted a multicenter case-control study among patients with cirrhosis (cases with early-stage HCC per Milan Criteria; controls without HCC) who underwent both a liver ultrasound and dynamic contrast-enhanced (DCE) AMRI within 6 months in 2012–2019. Two radiologists performed independent, blinded interpretations of both exams for HCC detection and scored exam quality as no/mild, moderate, or severe limitations. Associations between exam quality, patient characteristics, and HCC detection were assessed by odds ratios (OR). Results Of 216 cases and 432 controls, severe limitations were reported in 7% and 8% of ultrasounds and DCE-AMRIs, respectively. Severe limitations at ultrasound were associated with obesity (OR 2.08, 95%CI [1.32–3.32]) and metabolic dysfunction-associated steatotic liver disease (MASLD) (OR 1.98 [1.12–3.44]) but not for DCE-AMRI. Decompensated cirrhosis (Child-Pugh C) was associated with severe limitations for both ultrasound (OR 2.54 [1.37–4.58]) and DCE-AMRI (OR 3.96 [2.36–6.58]). Compared to exams with no/mild limitations, exams with severe limitations had lower sensitivity for ultrasound (79.6% vs. 21.7%, P < 0.001) and AMRI (86.1% vs. 50.0%, P = 0.001). In patients in whom ultrasound was severely limited, DCE-AMRI had significantly higher odds of early-stage HCC detection than ultrasound (OR 8.23 [1.25–54.02]). Conclusions HCC detection by DCE-AMRI may be preferred in patients with severe limitations at ultrasound due to obesity and MASLD. Both modalities remain limited for patients with decompensated cirrhosis, for whom alternative strategies may be needed.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RP210041)
- National Institutes of Health (K08CA259536, U01 CA271887)
This publication has 59 references indexed in Scilit:
- Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic reviewLiver Transplantation, 2022
- Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinomaCancer, 2022
- Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteriaHepatology, 2022
- GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosisHepatology, 2021
- Estimated Projection of US Cancer Incidence and Death to 2040JAMA Network Open, 2021
- Abbreviated‐protocol screening MRI vs. complete‐protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI‐RADS v2018Journal of Magnetic Resonance Imaging, 2019
- Predictors of Ultrasound Failure to Detect Hepatocellular CarcinomaLiver Transplantation, 2018
- LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary featuresAbdominal Radiology, 2018
- US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinomaAbdominal Radiology, 2017
- MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular CarcinomaJAMA Oncology, 2017